Opinion Article Open Access
Volume 8 | Issue 2 | DOI: https://doi.org/10.33696/immunology.8.256
A Multidisciplinary Framework for the Management of Serious Adverse Events from Modern Anticancer Therapies
Saqib Abbasi1,*, Nina Mathew1, Nanuli Gvazava1, Daniel R. Tilden2, Anjulie Quick3, Aiman Zafar2, Jennifer Klemp1, Adela R. Cardones4, Jason Sokol3, Leigh Eck2, Weijing Sun1
- 1The University of Kansas Cancer Center, Medical Oncology, Kansas City, Kansas, United States
- 2University of Kansas Medical Center, Endocrinology, Kansas City, Kansas, United States
- 3University of Kansas Medical Center, Ophthalmology, Kansas City, Kansas, United States
- 4University of Kansas Medical Center, Dermatology, Kansas, United States
Corresponding Author
Saqib Abbasi, saqabb@gmail.com
Received Date: April 28, 2026
Accepted Date: September 01, 2026
Abbasi S, Mathew N, Gvazava N, Tilden RD, Quick A, Zafar A, et al. A Multidisciplinary Framework for the Management of Serious Adverse Events fom Modern Anticancer Therapies. J Cell Immunol. 2026;8(2):74–80.
Copyright: © 2026 Abbasi S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
VA-Radiation Oncology Quality Surveillance Program: Enhancing Quality Measure Data Capture, Measuring Quality Benchmarks and Ensuring Long Term Sustainability of Quality Improvements in Community Care
Delivery of high-quality cancer care improves oncologic outcomes, including survival and quality of life. The VA National Radiation Oncology (NROP) established the VA Radiation Oncology Quality Surveillance Program (VAROQS) which has developed clinical quality measures (QM) as a measure of quality indices in radiation oncology. We sought to measure quality in community care, assess barriers to data capture, and develop solutions to ensure long term sustainability of continuous quality improvement for veterans that receive dual care, both within the VA and in non-VA community care (NVCC).
The Challenge of Cognitive Dissonance in the Delivery of Precision Medicine in Veterinary Oncology
The use of molecular and genomic analysis of a cancer as a means to define a patient-specific treatment is interchangeably referred to as Precision Medicine, Personalized Medicine, or Genomically-directed medicine (herein, collectively PMED). In the foregoing commentary we have focused on PMED approaches related to treatment selection and do not prioritize the development of novel molecular assays used to guide patient diagnostics or prognostication.
Commentary on “Epigenetically Altered T Cells Contribute to Lupus Flares”
The recently published manuscript entitled “Epigenetically Altered T Cells Contribute to Lupus Flares” summarizes recent advances in our understanding of how the environment alters the immune system to cause flares of systemic lupus erythematosus (SLE) in genetically predisposed people, and why it affects women approximately 9 times more often than men
CTLA-4 and PD-L1 or PD-1 Pathways: Immune Checkpoint Inhibitors and Cancer Immunotherapy
The immune system developed certain checks and balance to control or inhibit the reactivity against normal cells of the body. Uncontrolled immune responses to the non-self entities such as bacteria, viruses, parasites, or mutated self-antigens can cause an inflammatory reaction and autoimmune diseases.
Kinetin/N6-furfuryladenine: A New Neurodegenerative Disease Lead from an Old Plant Cytokine
N6-fufuryladenine (N6FFA), or kinetin, has a long history as a plant cytokine with practical applications in agriculture. This adenosine analog is now commonplace in natural product small molecule chemical screening libraries, and as such has been discovered as active in mammalian disease pathways that include Parkinson’s disease, Huntington’s disease (HD) and Familial Dysautonomia.